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Bacterial killing via a type IV secretion system
Diorge P. Souza1, Gabriel U. Oka1, Cristina E. Alvarez-Martinez1,2, Alexandre W. Bisson-Filho1, German Dunger1,
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Type IV secretion systems (T4SSs) are multiprotein complexes that transport effector
proteins and protein–DNA complexes through bacterial membranes to the extracellular
milieu or directly into the cytoplasm of other cells. Many bacteria of the family
Xanthomonadaceae, which occupy diverse environmental niches, carry a T4SS with unknown
function but with several characteristics that distinguishes it from other T4SSs. Here we show
that the Xanthomonas citri T4SS provides these cells the capacity to kill other Gram-negative
bacterial species in a contact-dependent manner. The secretion of one type IV bacterial
effector protein is shown to require a conserved C-terminal domain and its bacteriolytic
activity is neutralized by a cognate immunity protein whose 3D structure is similar to
peptidoglycan hydrolase inhibitors. This is the first demonstration of the involvement of a
T4SS in bacterial killing and points to this special class of T4SS as a mediator of both
antagonistic and cooperative interbacterial interactions.
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B
acterial cells are continuously interacting with other
bacterial and eukaryotic cells in a relentless battle for
survival. These interactions have driven the evolution of
several mechanisms by which they quickly deploy proteinaceous
and nucleic acid effectors that manipulate the behaviour of the
target organism, often resulting in growth inhibition or death1–6.
Distinct among these mechanisms are the type III, type IV and
type VI secretion systems (T3SS, T4SS and T6SS, respectively)
that are all capable of transferring proteins, and in the case of the
T4SS, protein–DNA complexes, directly into neighbouring cells
in a contact-dependent manner1–3. All three of these systems
have been shown to be able to inject virulence factors into
eukaryotic hosts, but only the T6SSs have been shown to deliver
lethal toxins into bacterial cells7.
T4SSs are perhaps the most versatile of the macromolecular
transport systems, being essential for host colonization by many
medically important microbes8–13, the horizontal transfer of
genetic material between bacteria and from bacteria to plants2 as
well as the special cases of the Helicobacter pylori DNA uptake14
and Neisseria gonorrhoeae DNA release15 systems. The
prototypical T4SS is that of the plant pathogen Agrobacterium
tumefaciens that uses its Vir system to cause tumours in most
dicotyledonous species16. T4SSs are generally made up of a core
set of 12 proteins, named VirB1–VirB11 plus VirD4 with a
structural organization that is only now being elucidated: (i) a set
of three cytoplasmic ATPases (VirB4, VirB11 and VirD4) that
energize secretion; (ii) a periplasmic core complex made up of 14
repeats of a VirB7–VirB9–VirB10 trimer, in which VirB10 inserts
into both inner and outer membranes and VirB7 is an outer
membrane lipoprotein; (iii) an inner membrane complex that
includes VirB3, VirB6 and VirB8; (iv) an extracellular pilus
formed by VirB2 and VirB5; and (v) the periplasmic
transglycosylase VirB1 (refs 2,17–19).
Many bacteria of the family Xanthomonadaceae, which occupy
diverse environmental niches, carry a T4SS with unknown
function but with several characteristics that distinguishes it
from other T4SSs20,21. One of these distinguishing features is that
the Xanthomonas citri (Xac) VirD4 protein (VirD4XAC2623), a
homologue of the coupling protein that recruits effectors to the
T4SS for secretion2, interacts with a set of uncharacterized
Xanthomonas VirD4-interacting proteins (XVIPs) that all contain
a conserved C-terminal domain termed XVIPCD (XVIP-
conserved domain)20. In this study, we show that these XVIPs
are toxins secreted by the Xanthomonas T4SS, that secretion is
dependent on the XVIPCD and that this special T4SS is used by
Xanthomonas to kill other bacterial cells, thereby providing a
competitive growth advantage in mixed bacterial communities.
Results
A hypothesis for a new physiological role for a T4SS. The Xac
XVIPs are highly diverse in size and architecture and lack a
canonical signal sequence. Six Xac XVIPs (XAC0466, XAC0574,
XAC1918, XAC2609, XAC2885 and XAC3634) are predicted to
act within the periplasm as peptidoglycan (PG)-binding proteins,
PG glycohydrolases, lytic transglycosylases, PG peptidases or
lipases (Fig. 1a). Furthermore, the genes of these proteins,
plus one other containing an HExxH metallopeptidase motif
(XAC0096), are found downstream to, and potentially co-tran-
scribed with, genes that code for proteins with unknown func-
tions with predicted lipoprotein signal peptides that are expected
to localize them within the bacterial periplasm (Fig. 1). One XVIP
(XAC2609) has a complete PG-binding domain (residues
219–280) and a region (residues 30–120) with similarity to the
catalytic region of proteins of glycoside hydrolase family 19
(GH19) that possess chitinase- or lysozyme-like activities22
(Fig. 1). XAC2609 has been shown to interact with the putative
periplasmic lipoprotein XAC2610 and both are coded by genes
within the Xac chromosomal T4SS vir locus20. These
characteristics are very similar to those observed for certain
T6SS effectors with hydrolytic activities against conserved PG and
phospholipid components of the bacterial cell wall and their
cognate immunity proteins23,24. On the basis of these
observations, one hypothesis is that the Xac T4SS could secrete
toxins participating in toxin–immunity protein systems.
XAC2609 lyses PG and XAC2610 is its inhibitor. To test the
above hypothesis, we performed a set of in vitro experiments to
determine whether XAC2609 has the predicted lysozyme-like
activity. Purified recombinant XAC2609 is able to degrade PG
from the Gram-positive Micrococcus luteus (Fig. 2a), reduces the
optical density and introduces a marked lag in the growth curve
of Bacillus subtilis cultures (Fig. 2b), and results in B. subtilis cell
lysis (Fig. 2d). These activities are maintained in an XAC2609
fragment lacking the XVIPCD (XAC2609(1–308); Fig. 2a) but are
not observed when using a mutant XAC2609(1–308) in which
glutamic acid 48 within the predicted active site of the GH19
domain was changed to alanine (Fig. 2a,e). We observed similar
lytic activity against PG (Fig. 2a) and B. subtilis (Fig. 2g) for a
second XVIP, XAC0466, that has a domain architecture similar to
XAC2609 plus a PG amidase domain (Fig. 1a). Furthermore, the
XAC2609 lytic activity is inhibited by the addition of XAC2610
(Fig. 2a,b and f). XAC2610 is a specific inhibitor of XAC2609
since it was not able to inhibit the lytic activities of XAC0466 or
hen egg white lysozyme (Fig. 2a). We also observed that
XAC2609 and XAC2610 can be co-immunoprecipitated from Xac
cells (Supplementary Fig. 1a) and that XAC2610 interacts with
the catalytic XAC2609 N-terminal domain but not with the
XVIPCD domain in vitro (Supplementary Fig. 1b). Due to
these characteristics, we will therefore now refer to XAC2609
as X-TfeXAC2609 (for Xanthomonadaceae-T4SS effector) and
to XAC2610 as X-TfiXAC2610 (for Xanthomonadaceae-T4SS
immunity protein).
X-TfiXAC2610 structure is similar to PG hydrolase inhibitors.
The X-TfiXAC2610 protein does not share sequence similarity with
any proteins of known function. We therefore determined the
crystal structure of X-TfiXAC2610(55–267) (a fragment lacking the
signal peptide, lipobox lipidation signal and a predicted
unstructured region). Details of X-TfiXAC2610(55–267) crystal-
lization, data collection and refinement are found in the Methods
section and Supplementary Table 1. X-TfiXAC2610 has an
N-terminal modified b-sandwich fold that includes a conserved
integrin-like Ca2þ -binding loop and an intramolecular disulfide
bond, connected via a single a-helix to a C-terminal domain
made up of an uncommon single-layer six-stranded antiparallel
b-sheet (Fig. 3a). A more detailed description of the X-TfiXAC2610
structure, including the Ca2þ -binding loop and its semblance to
a b-propeller fragment, is presented in Supplementary Fig. 2.
Supplementary Figure 3 presents small-angle X-ray scattering
data that is consistent with a monomeric structure in solution.
What is most interesting about the X-TfiXAC2610 structure is that
among its closest topological homologues are the periplasmic
I-type lysozyme inhibitor PliI25,26 (Fig. 3b) and the P. aeruginosa
immunity protein Tsi1 (Fig. 3c) that inhibits the lytic PG
DL-endopeptidase activity of its cognate T6SS effector protein
Tse1 (refs 7,27; see also Supplementary Fig. 4). This topological
similarity includes the superposition of the ion-binding sites of
the X-TfiXAC2610 and PliI proteins (Fig. 3d; Supplementary
Fig. 4a). The above in vitro and structural results show that
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X-TfiXAC2610 is in fact the cognate immunity protein of the
X-TfeXAC2609 PG hydrolase toxin.
X-Tfe secretion is T4SS dependent and requires a XVIPCD.
We next tested whether X-TfeXAC2609 is secreted in a manner
dependent on the Xac T4SS. For this, we employed Xac DvirD4
and DvirB7 mutants, both of which are expected to abolish
secretion of all T4SS substrates since VirD4 is the
coupling protein required for recognition of T4SS substrates2 and
deletion of the Xac virB7 gene results in the disappearance of not
just VirB7 but also VirB9 and VirB10 (ref 21), the principal
components of the T4SS core complex28. Fig. 4a (top row) and
Fig. 4b show that when Xac cells are spotted on nitrocellulose
filters layered on Luria-Bertani (LB) agar plates, allowed to grow
for 12 h and the cells washed away, we could not detect
any secreted X-TfeXAC2609 bound to the membrane since the
background immunofluorescence signals of all Xac strains alone
are the same as that observed for the Dxac2609 mutant. However,
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Figure 1 | Xac X-Tfe proteins and their respective putative X-Tfi immunity proteins. (a) Gene names and domain architectures of the 13 Xac X-Tfes.
All these proteins contain a Xanthomonas VirD4-interacting protein conserved domain (XVIPCD)20. PGB, peptidoglycan-binding domain; GH19,
glycohydrolase family 19; SLT, soluble lytic transglycosylase; Ca2þ , Ca2þ -binding domain; AHH, putative nuclease domain. (b) Gene names of putative
lipoprotein signal peptide-containing Xac immunity proteins (X-Tfis) and sequences of the putative lipoprotein signal peptides. All seven of these genes are
upstream of, and potentially co-transcribed with, the neighbouring X-Tfe gene. Lipoprotein signal peptides are characterized by an N-terminal basic region
(basic residues coloured blue), a central hydrophobic region (underlined) followed by an [LVI]-[ASTVI]-[AGS]-C lipobox motif (red)68. Also indicated are
the positions of the putative translation initiation codons relative to those found in the original annotation of the Xac genome69.
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Figure 2 | X-TfeXAC2609 is a peptidoglycan hydrolase and X-TfiXAC2610 is its specific inhibitor. (a) Analysis of M. luteus peptidoglycan degradation,
as determined by decreases in optical density (OD) at 650 nm of cell wall suspensions treated with purified proteins X-TfiXAC261055–267, 2610; full-length
X-TfeXAC2609, 2609; X-TfeXAC2609(1–308) N-terminal fragment (residues 1–308), 2609Nt; X-Tfe
XAC2609
(1–308_E48A) N-terminal fragment E48A mutant,
2609Nt-E48A; X-TfeXAC0466(1–475) N-terminal fragment (residues 1–475), 0466Nt; hen egg white lysozyme, HEWL. A suspension without the addition of
any protein (buffer) is shown as a control. Error bars, s.d.; n¼ 3. (b) Growth curves at 30 C of B. subtilis cells after incubation for 10min without proteins
(blue), with X-TfeXAC2609 (red), X-TfiXAC2610 (purple) or a mixture of both proteins (green; error bars, s.d.; n¼ 3). (c–g) Fluorescence microscopy of
membrane-labelled B. subtilis cells after incubation for 5min with c, buffer; d, X-TfeXAC2609; e, X-TfeXAC2609(1–308_E48A); f, a X-Tfe
XAC2609 -X-TfiXAC2610
mixture; g, X-TfeXAC0466(1–475). Scale bar, 5 mm.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7453 ARTICLE
NATURE COMMUNICATIONS | 6:6453 | DOI: 10.1038/ncomms7453 | www.nature.com/naturecommunications 3
& 2015 Macmillan Publishers Limited. All rights reserved.
extracellular X-TfeXAC2609 is detected when wild-type (WT) Xac
cells are mixed with an equal number of E. coli cells before
spotting (Fig. 4a, bottom row and Fig. 4b). Moreover, E. coli-
induced X-TfeXAC2609 secretion is abolished in the DvirD4 and
DvirB7 strains and restored when plasmids for expression of
VirD4 or VirB7 proteins are introduced in these strains
(Fig. 4a,b). These results show that X-TfeXAC2609 is secreted by
Xac on contact with E. coli cells in a T4SS-dependent manner.
X-TfeXAC2609 secretion is dependent on its XVIPCD since
extracellular X-TfeXAC2609 could only be detected in the
experiments using a Xac Dxac2609 mutant carrying a plasmid
expressing full-length X-TfeXAC2609 but not in mutant strains
carrying empty plasmid or a plasmid that directs the expression
of an X-TfeXAC2609 fragment lacking the XVIPCD (Fig. 4a,b).
Detection of extracellular X-TfeXAC2609 in these experiments is
not due to E. coli-induced Xac lysis since all Xac strains (except
the uncomplemented Dxac2609 mutant), including both DvirD4
and DvirB7, produce intracellular X-TfeXAC2609 (Fig. 4c).
The Xac T4SS confers an advantage in growth competition
experiments. We then asked whether the T4SS confers a com-
petitive advantage to Xac in growth competition experiments
against other bacterial species. While there are no significant
differences in the growth curves of the Xac WT and DvirD4 and
DvirB7 mutant strains in liquid culture or on semi-solid media
(Supplementary Fig. 5), when Xac cells carrying a plasmid for the
expression of cyan fluorescent protein (CFP) and E. coli cells
expressing yellow fluorescent protein (YFP) were mixed and
allowed to grow together as a co-culture on agar plates, we
observed a significant increase in both the number and the size of
the yellow E. coli colonies/zones in the cyan background of the
Xac DvirB7 strain when compared with that of the Xac WT strain
(Fig. 5a,b). Xac competitiveness is recovered when the VirB7
protein is expressed in the DvirB7 strain (Fig. 5c). The same
phenomenon was observed in competition experiments using Xac
DvirD4 and DvirB7 mutants expressing green fluorescent protein
(GFP) and non-fluorescent E. coli (Supplementary Fig. 6a). Fur-
thermore, after 38 h of co-culture growth, the Xac/E. coli ratio is
two orders of magnitude lower when Xac DvirB7 strain is used, as
compared with when the Xac WT strain or Xac DvirB7 strain
carrying a plasmid for VirB7 expression are used (Fig. 5d). To
further test whether T4SS mediates it effects in a contact-
dependent manner, we placed a 0.2-mm pore filter between Xac
and E. coli cells. Interestingly, the T4SS-dependent growth defect
of Xac DvirB7 and DvirD4 mutant strains completely disappeared
under this condition (Supplementary Fig. 6b), showing that direct
contact is required for this T4SS function. Xac competitiveness
against Chromobacterium violaceum, another Gram-negative
species from a different bacterial class (Betaproteobacteria), was
also observed to be T4SS dependent in the experiments similar to
those shown in Fig. 5 (Supplementary Fig. 7).
Figure 3 | X-TfiXAC2610 is structurally similar to peptidoglycan hydrolase
inhibitors. (a) Ribbon representation of the X-TfiXAC2610 model (residues
55–267). A Ca2þ ion and Ca2þ -coordinating residues are shown as a
sphere and sticks, respectively. (b) Superposition of X-TfiXAC2610 (yellow)
and PliI (light blue, PDB code 3OD9, ref. 26). (c) Superposition of
X-TfiXAC2610 (yellow) and Tsi1 (pink). Tse1, the hydrolase inhibited by Tsi1, is
shown in green in the Tsi1–Tse1 complex structure (PDB accession code
3VPJ, ref. 27). Stereo versions of b and c can be found in Supplementary
Fig. 4. (d) Superposition of the X-TfiXAC2610 and PliI ion-binding sites.
Dashed lines show the pentagonal bipyramidal coordination of Ca2þ in
X-TfiXAC2610. The sticks colouring scheme for b and d are: C, yellow in
X-TfiXAC2610 and light blue in PliI; O, red; N, blue; Ca2þ , yellow sphere;
coordinating water, red sphere; Naþ , light blue sphere. Search for structural
similarities were performed using the Dali server60. The r.m.s.d., fraction
of the chain for the superposition and % sequence identity of X-TfiXAC2610
and Tsi1 are 3.4Å, 82% and 7% respectively. For the superposition of
X-TfiXAC2610 and PliI, these values are 3.7Å, 78% and 12% respectively.
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Figure 4 | X-TfeXAC2609 secretion requires a XVIPCD, a functional T4SS
and is stimulated by co-culture with E. coli cells. (a) Xac cells only (top
row) or 1:1 Xac:E. coli mixtures (bottom row) were spotted on nitrocellulose
filters layered on LB agar plates, allowed to grow for 12 h, the cells washed
away and bound X-TfeXAC2609 was immunodetected. The Xac wild-type
(WT) strain (carrying pBBR-5GFP and empty pBRA vector) and the derived
mutants (DvirD4, DvirB7 and Dxac2609) and complemented strains
(DvirD4þ virD4, DvirB7þ virB7, Dxac2609þ xac2609 and
Dxac2609þ xac2609Nt (X-TfeXAC2609 N-terminal fragment)) used are
indicated above each lane. (b) Integrated infrared fluorescence intensity of
X-TfeXAC2609 immunodetection from seven independent experiments
similar to those represented in a for Xac only (dark bars) and Xac:E. coli
mixtures (light bars). Intensities were normalized to those measured for the
WT Xac:E. coli mixture. Error bars, s.d. (c) Western blot detection of total
cellular X-TfeXAC2609 produced by Xac strains used in a. The full blot is
shown in Supplementary Fig. 9.
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The Xac T4SS mediates bacterial killing. The competitive
increment conferred by the Xac T4SS could be the result of
secretion of factors that inhibit the growth of competing bacterial
species or that promote direct killing of targeted adjacent cells. To
distinguish between these two hypotheses, we used time-lapse
microscopy to observe individual cells in Xac/E. coli co-cultures.
Figure 5e–g shows micrographs of single fields obtained shortly
after mixing equal amounts of Xac and E. coli cells on a thin
agarose surface. While we frequently observed the rapid lysis of
E. coli cells that were in direct physical contact with Xac WT cells
(Fig. 5e), we did not observe these events when the DvirB7 and
DvirD4 strains were used (Supplementary Fig. 8). Xac killing of
E. coli was restored using mutant strains carrying plasmids for
VirB7 or VirD4 expression (Fig. 5f,g). Supplementary Movie 1
presents a series of images separated by 300-ms intervals that
show that E. coli cell lysis is extremely rapid, with cells often
bursting in a seemingly explosive manner in o1 s to a few
seconds. By comparison, Xac cell lysis was very rarely observed in
these experiments. The rapid and violent cell death that
we observe contrasts with that which has been reported for
T6SS-mediated killing by Pseudomonas aeruginosa, in which
target cells change their morphology (cell rounding, blebbing and
plasmolysis) over a period of many minutes before lysis29,30.
Discussion
We have provided evidence that the Xac T4SS, and by extension
its homologues in other Xanthomonadaceae species, target toxins
(X-Tfes or XVIPs) to bacterial cells, thereby providing Xantho-
monas an advantage to survive in an environment populated by a
number of different bacterial species in a manner similar to that
recently described for several T6SSs29–33. Using the presence of a
XVIPCD as search criteria, we have identified 500 potential
X-Tfes in the public databases, of which all but two are derived
from members of the Xanthomonadaceae family (Table 1). Most
species that code for a Xanthomonadaceae-like T4SS code for
several X-Tfe proteins and, in most cases analysed so far, one
X-Tfe gene is found next to the gene of a T4SS component with
the remaining X-Tfe genes found spread throughout the genome.
Many of these proteins carry domains that may work to kill or
inhibit growth of other organisms. Especially abundant are lipase
domains34 and domains involved in binding or modification
of PG, found exclusively in bacterial cell walls35: for example,
PG-binding domain 1 (ref. 36), transglycosylase SLT37, peptidase
M23 (ref. 38), GH19 (refs 22,39) and NlpC/P60 (refs 38,40)
domains (Table 1). Other examples are the Zeta toxin domain
that produces an inhibitor of bacterial PG biosynthesis41, the
AHH domain likely involved in killing bacteria via its putative
nuclease activity42 and DUF2235 (ref. 43), a putative hydrolase
recently found to be present in T6SS effectors44 (Table 1). Both
Zeta toxin and AHH domains are found in toxin–antitoxin
systems where they are inhibited by specific immunity
proteins41,42.
It is important to note that of the 500 X-Tfes (XVIPs) analysed
in Table 1, a large majority has no recognizable domain other
than the C-terminal XVIPCD. Therefore, by studying the XVIP
repertoire, we can reasonably expect the number of activities of
this newly characterized T4SS and its effectors to expand. The
proposed general bacterial killing function for a large number
of Xanthomonadaceae-T4SS effectors may have interesting
biotechnological applications that lead to new drug targets and
ways of fighting other pathogenic bacteria that cause disease in
humans and plants. Furthermore, we speculate that some X-Tfes
could provide defence against eukaryotic microbes that prey on
Xanthomonads.
Finally, Ho et al.45 recently showed that P. aeruginosa uses its
T6SS to attack neighbouring cells carrying a mating pair
formation T4SS encoded by a conjugative plasmid. The initial
speculation was that this T4SS-induced T6SS counterattack
potentially blocks acquisition of parasitic foreign DNA.
However, since we have now demonstrated that some T4SSs
pose a more immediate lethal threat to neighbouring bacteria,
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Figure 5 | Xac kills E. coli cells in a T4SS-dependent manner. (a–c) Xac cells carrying a plasmid for the expression of CFP (cyan) and E. coli DH5a cells
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many bacterial species may have been under much stronger
evolutionary pressure to have evolved an automatic T6SS
counterattack response. This immediately suggests the
hypothesis that, since very few T4SS have been characterized to
date, T4SS-mediated bacterial killing may not be restricted to the
Xanthomonadaceae family, and may in fact be a more widespread
phenomenon.
Methods
Bacterial strains, growth conditions and cloning. Bacterial strains, oligonu-
cleotides and plasmids used in this study are described in Supplementary Table 2.
All strains were grown on LB or 2TY (2 yeast extract and tryptone) media.
Concentrations of the antibiotics used: 100 mgml 1 ampicilin, 20mgml 1
gentamicin, 100 mgml 1 spectinomycin, 15mgml 1 tetracycline, 100mgml 1
chloramphenicol and 30 mgml 1 kanamycin. For generation of the Xac Dxac2609
strain, B1 kb of the upstream and downstream regions of the xac2609 gene were
amplified by PCR from Xanthomonas citri subsp. citri strain 306 genomic DNA
and the two fragments were ligated to produce an in-frame deletion, leaving only
the region coding for the first 15 and last 12 codons. This sequence was then cloned
into the BamHI restriction site of the pNPTS138 suicide vector (M. R. Alley,
unpublished; described in Supplementary Table 2), thereby generating the
pNPTS138-2609 plasmid. For generation of the Xac DvirD4 strain, a DNA frag-
ment including the virD4 gene plus 0.55 kb upstream and downstream sequences
were amplified by PCR and cloned into the NdeI/HindIII sites of the pUC19 vector.
The resulting pUC19-virD4 vector was digested with the SacI restriction enzyme;
as the virD4 gene has three of these sites, the digestion and subsequent re-ligation
of the plasmid removed an internal fragment of 0.75 kb of virD4, generating the
pUC19-DvirD4. This strategy removed 251 codons of the central region of the
gene, leaving the first 256 and the last 50 codons of virD4. This plasmid was
digested with SpeI/SalI and the resulting DNA containing the virD4 gene fragment
plus 0.55 kb upstream and downstream sequences was cloned into the pNPTS138,
thereby generating the pNPTS138-virD4 plasmid. In-frame deletions in the virD4
and xac2609 genes were obtained by a two-step allelic exchange procedure as
previously described for the virB7 gene21 using the pNPTS138-2609 and
pNPTS138-virD4 vectors. For complementation of Xac mutant strains, genes
virB7XAC2622, virD4XAC2623 and xac2609 (coding the full-length protein (residues
1–431) or its N-terminal domain (residues 1–306)) were cloned in the pBAD24-
derived vector pBRA (M. Marroquin, unpublished; described in Supplementary
Table 2), which contains an arabinose-induced promoter that is constitutively
active in Xac. Genes virB7, virD4, xac2609 and xac2609Nt were amplified by PCR
from Xac306 genomic DNA and PCR products were cloned directly into the
NcoI/SalI sites of pBRA. A recombinant XAC2610 (GenBank accession
code AAM37459) fragment consisting of residues 22–267 fused to an
N-terminal His-tag (X-TfiXAC2610(His-22–267)) and full-length XAC2609 (residues
1–431; X-TfeXAC2609(1–431); GenBank accession code AAM37458) were expressed
as described previously20. In brief, DNA coding for residues 55–267 of XAC2610
(X-TfiXAC2610(55–267)) and N terminus (residues 1–308; X-TfeXAC2609(1–308)) and C
terminus (residues 311–431; X-TfeXAC2609(311–431)) fragments of XAC2609 were
amplified by PCR from Xac genomic DNA and cloned into the pET11a plasmid
(Novagen) using the NdeI and BamHI cloning sites. The pET11a-XAC26091–308
vector was used as a DNA template for the generation of the pET11a-XAC2609-
E48A plasmid that codes for X-TfeXAC2609(1–308_E48A) (the X-TfeXAC2609(1–308)
protein with a Glu 48 to Ala mutation), using the QuikChange Site-Directed
Mutagenesis Kit (Agilent Technologies). DNA coding for the N-terminal fragment
of XAC0466 (residues 1–475; X-TfeXAC0466(His-1–475); GenBank accession code
AAM35357) was cloned into the pET28a vector using the NdeI and BamHI sites,
expressing a protein fused to an N-terminal His-tag. All plasmids were confirmed
by DNA sequence analysis.
Protein expression and purification. E. coli BL21(DE3)RP strain (Novagen) was
used for the expression of the recombinant proteins. Cells were grown in 2TY at
37 C and recombinant proteins were induced at mid-log phase for 3–4 h by the
addition of 0.5mM isopropyl-b-D-thiogalactoside. Cells were then harvested and
lysed by sonication employing a Vibra-Cell VCX-500 instrument (Sonics &
Materials Inc.). The first chromatographic purification step was performed with a
Q-sepharose anion exchange column (GE Healthcare) for all X-TfeXAC2609 and
X-TfiXAC2610 constructions. The second chromatographic step was an affinity
purification using a nickel chelate column for X-TfiXAC2610(His-22–267), a size
exclusion purification with a 26/600 Superdex 75 column for X-TfiXAC2610(55–267),
X-TfeXAC2609(1–308) and X-TfeXAC2609(311–431) or a 26/600 Superdex 200 column
for X-TfeXAC2609(1–431) and X-TfeXAC2609(1–308_E48A). X-TfeXAC0466(His-1–475) was
purified using a nickel chelate column.
PG hydrolase activity assay. Micrococcus luteus cell wall suspensions (Sigma)
with an optical density at 650 nm (OD650 nm) of 0.7 (0.8mgml 1) in 50mM
sodium acetate (pH 5.0) and 2mM CaCl2 were incubated in triplicate for
20min at 30 C with the following treatments: (i) without proteins (buffer),
(ii) with X-TfiXAC2610(55–267), (iii) X-TfeXAC2609(1–431), (iv) X-TfeXAC2609(1–308),
Table 1 | Domains found in 500 proteins containing XVIPCDs.
Domain* Description Xac X-Tfes
that contain
this domain
Other examples found in other organisms
GenBank accession code—Organism
No. in 500
proteins
analysed*
PG-binding domain 1 Binding to PG XAC2609
XAC0466
XAC3634
EIL93106—R. fulvus Jip2
EKQ64038—X. axonopodis. pv. malvacearum
CAJ25482—X. campestris pv. vesicatoria
107
Lipase 3/DUF2974 Hydrolysis of ester linkages in triglycerides XAC0574
XAC2885
CCG35840—X. citri pv. mangiferaeindicae
EGD17149—X. gardneri ATCC 19865
61
GH19 Hydrolysis of glycosidic bonds in chitin and PG XAC2609
XAC0466
EMF61220—S. maltophilia EPM1
CAP51046—X. campestris. pv. campestris
15
Peptidase M23 Hydrolysis of peptide bonds in PG XAC0466 EMI48206—S. maltophilia AU12-09
AEL09382—X. campestris pv. raphani
7
DUF2235 Uncharacterized alpha/beta hydrolase domain Not found CBA16126—X. albilineans GPE PC73
CBA16292—X. albilineans GPE PC73
6
Zeta toxin Phosphorylation of the PG precursor UNAG;
inhibition of PG synthesis
Not found AEM51053—S. maltophilia JV3
EMI51042—S. maltophilia AU12-09
3
AHHw Nuclease participating in toxin–antitoxin system XAC3266 AGH78749—X. axonopodis Xac29-1
AGI06866—X. citri subsp. citri Aw12879
3
SLTz Hydrolysis of glycosidic bonds in PG XAC3634|| EMI48206—S. maltophilia AU12-09
WP_016901345—X. arboricola pv. juglandis
2
NlpC/P60 Hydrolysis of peptide bonds in PG Not found WP_017913944—Xanthomonas sp. SHU308
WP_017910175—Xanthomonas sp. SHU199
2
GH19, glycoside hydrolase family 19; PG, peptidoglycan; SLT, soluble lytic transglycosylase; Xac, Xanthomonas citri; XVIP, Xanthomonas VirD4-interacting protein; XVIPCD, XVIP-conserved domain
*Analysis of the PFAM-A domains found in 500 proteins containing the XVIPCD. The proteins were identified by PSI-BLASTusing the X-TfeXAC2609 XVIPCD sequence as the initial query. Of these 500
proteins, all but two are found in species of the Xanthomonadaceae family: Xanthomonas spp.: 377 proteins; Stenotrophomonas spp.: 101 proteins; Pseudomonas geniculata: 8 proteins; Dyella ginsengisoli:
5 proteins; Pseudoxanthomonas spadix: 4 proteins; Rhodanobacter fulvus: 2 proteins; Lysobacter spp.: 1 protein. The remaining two proteins were found in Pseudomonas syringae and Catenibacterium mitsuokai.
wSeven other XVIPs possibly have an AHH domain, although the matches were considered insignificant by PFAM (e-value: 0.012–0.0027).
z15 other XVIPs possibly have a SLT domain, although the matches were considered insignificant by PFAM (e-value: 0.11–0.0009). All 17 XVIPs with a putative SLT domain also have a PG-binding
domain 1.
||While not identified by PFAM, XAC3634 has a predicted N-terminal SLT according to the Conserved Domain Database70 (see Fig. 1).
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(v) X-TfeXAC2609(1–308_E48A), (vi) X-TfeXAC0466(His-1–475), (vii) HEWL,
(viii) X-TfeXAC2609(1–431) plus X-TfiXAC2610(55–267), (ix) X-TfeXAC2609(1–308)
plus X-TfiXAC2610(55–267), (x) X-TfeXAC0466(His-1–475) plus X-TfiXAC2610(55–267)
or (xi) HEWL plus X-TfiXAC2610(55–267). X-TfeXAC2609-derived proteins,
X-TfeXAC0466(His-1–475) and HEWL, were used at 1 mM concentration, while
X-TfiXAC2610(55–267) was present at 2 mM. The reactions were stopped with the
addition of 500mM sodium carbonate. Cell wall degradation was monitored as a
decrease in OD650 nm.
Bacterial growth inhibition assay. Bacillus subtilis PY79 cells were grown in
2TY to log phase (OD600 nm¼ 0.5). Cells were harvested by centrifugation and
resuspended to an OD600 nm of 0.8 in 10mM sodium acetate pH 5.0 and 1mM
MgCl2. Incubations were performed in triplicate for 10min at 30 C with only
buffer or buffer containing 1 mM X-TfeXAC2609(1–431) or 2 mM X-TfiXAC2610(55–267)
or 1 mM X-TfeXAC2609(1–431) plus 2 mM X-TfiXAC2610(55–267). The bacteria were then
diluted with nine volumes fresh 2TY medium and subsequent growth at 30 C
was monitored by measuring OD600nm.
Bacillus subtilis lysis by X-Tfes. Bacillus subtilis PY79 cells were grown in LB
to OD600 nm¼ 0.5, harvested by centrifugation and resuspended to an OD600 nm
of 0.8 in 10mM sodium acetate (pH 5.0), 1mM MgCl2. Incubations were
performed with only buffer or buffer containing (i) 1 mM X-TfeXAC2609(1–431),
(ii) 1 mM X-TfeXAC2609(1–308), (iii) 1 mM X-TfeXAC2609(1–308_E48A), (iv) 2 mM
X-TfiXAC2610(55–267), (v) 1 mM X-TfeXAC2609(1–431) plus 2 mM X-TfiXAC2610(55–267),
(vi) 1 mM X-TfeXAC2609(1–308) plus 2 mM X-TfiXAC2610(55–267), (vii) 1 mM
X-TfeXAC0466(His-1–475) or (viii) 1 mM HEWL. After 5min of treatment at 23 C,
cells were centrifuged, washed, resuspended in 2TY and mounted on slides
covered with a layer of 25% LB plus 1.5% agarose. Membranes were stained with
FM1-43 or FM5-95 (Molecular Probes) at a final concentration of 1 mgml 1 and
the stained cells were analysed by fluorescence microscopy.
Fluorescence microscopy. Microscopy was carried out using a Nikon Eclipse Ti
microscope equipped with filters for GFP (GFP-3035B-000-ZERO, Semrock), CFP
(CFP-2432A-000-ZERO, Semrock), YFP (YFP-2427-000-ZERO, Semrock) and
membrane visualization (Texas Red BrightLine set; TXRED4040-B, Semrock), a
Plan APO VC Nikon 100 objective (numerical aperture¼ 1.4), a CFI Plan Apo
Lambda Nikon 2 objective and an Andor EMCCD i-Xon camera. The exposure
times varied from 0.2 to 1 s. Images were processed and analysed using the pro-
grams Nis Elements (version 3.07; Nikon) and ImageJ (http://rsbweb.nih.gov/ij/).
Antibody production, immunoprecipitation and immunoblot. Rabbit polyclonal
antibodies were produced against X-TfeXAC2609(1–431) and X-TfiXAC2610(His-22–267).
Xac total cell lysates from WT and DvirB7XAC2622 (DB7) strains were used for
immunoprecipitation experiments with pre-immune serum or anti-X-TfiXAC2610
serum (1:1,000 dilution), followed by immunoblots with anti-X-TfeXAC2609
and anti-X-TfiXAC2610 antibodies (1:1,000 dilution), performed as previously
described21. Pre-immune serum, from the same animal later immunized with
X-TfiXAC2610, was used as a negative control.
Fluorescence spectroscopy. Fluorescence assays were measured employing
AVIV ATF-105 and Hitachi F-4500 fluorometers. Qualitative protein–protein
interaction assays were carried out using 1 mM protein alone (X-TfiXAC2610(55–267),
X-TfeXAC2609(1–431), X-TfeXAC2609(1–308) and X-TfeXAC2609(311–431)) or combina-
tions of X-TfiXAC2610(55–267) and one of the three X-TfeXAC2609 fragments in
20mM Tris-HCl pH 7.5, 50mM NaCl, 3mM EGTA and 4mM CaCl2. Samples
were pre-equilibrated at 25 C for 2min, excited at 295 nm (bandwidth of 2.5 nm)
and fluorescence emission was recorded from 300 to 400 nm (bandwidth of 2.5 nm)
at 0.2-nm intervals. The results of three experiments were averaged.
Crystallization, data collection and processing. Vapour diffusion sitting drop
crystallization screens at 18 C were performed for X-TfiXAC2610(His-22–267), but no
crystals were obtained. Two weeks incubation of this protein at room temperature
produced an B23 kDa proteolytic fragment that formed thin needle-like crystals.
The N-terminal sequence of this fragment was determined by Edman degradation
using a Sequenator model PPSQ-23 (Shimadzu) and MALDI-ToF measurements
employing an Ettan MALDI-ToF mass spectrometer (GE Healthcare). The
sequence was found to begin at residue 56 and mass spectroscopy analysis was
consistent with a fragment consisting of X-TfiXAC2610 residues 55–267. Recombi-
nant X-TfiXAC2610(55–267) protein (400 mM dissolved in 10mM Tris-HCl pH 7.0,
20mM NaCl) was submitted to crystallization trials and crystals were observed
after 2 weeks over a reservoir solution containing 100mM Bis-Tris-HCl pH 5.5,
200mM (NH4)2SO4 and 25% (w/v) PEG3350. Crystals were transferred to
reservoir solution supplemented with 20% (v/v) glycerol and flash frozen at 100K.
X-ray diffraction data were collected using an in-house Rigaku MicroMax-007 HF
microfocus rotating Cu anode generator (Institute of Chemistry, University of
Sa˜o Paulo) and the beamline W01B-MX2 of the Brazilian Synchrotron Light
Laboratory (LNLS)46. The diffraction data were indexed, integrated and scaled
using d*TREK47 and HKL2000 (ref. 48). Data collection statistics are shown in
Supplementary Table 1.
X-ray structure determination and refinement. The crystal structure of
X-TfiXAC2610(55–267) was determined by SIRAS (single isomorphous replacement
with anomalous scattering) using crystals soaked for 5min with reservoir solution
supplemented with 20% (v/v) glycerol and a saturated solution of mercury acetate.
The initial phase estimation was carried out using SHELXD49 and autoSHARP50,
followed by automatic model building by ARP/wARP51. The model was
subsequently refined with the program Coot52 with rounds of TLS53 and restrained
refinement in Refmac554 from the CCP4 package55. Model quality was checked by
Coot, Refmac5, MolProbity56, Rampage57 and PROCHECK58. Clear electron
density was visible for all residues except for the first four amino acids (residues
55–58) that were not, therefore, included in the model. The electron density of
some specific exposed loops (residues 59–60, 139–143, 218–220 and 245–249) had
a relatively lower signal-to-noise level but was sufficient to model their backbones
with confidence. A total of 180 water molecules and a calcium ion were also
modelled. The final model has Rfactor and Rfree of 0.200 and 0.241, respectively
(Supplementary Table 1). Figures were prepared using PYMOL (http://
www.pymol.org) and protein topology schemes with TopDraw 59. The coordinates
of the X-TfiXAC2610(55–267) X-ray crystal structure were deposited in the PDB under
accession code 4QTQ. Search for structural similarities were performed using the
Dali server60. The Z-score, root mean squared deviation, number of residues
superposed and fraction of the chain for the superposition of X-TfiXAC2610 and
Tsi1 are 6.5, 3.4 Å, 120 and 82%, respectively, and for the superposition of
X-TfiXAC2610 and PliI are 4.9, 3.7 Å, 95 and 78%.
Small-angle X-ray scattering (SAXS). SAXS experiments were collected at the
D11A-SAXS1 beamline at the LNLS in Brazil. The radiation wavelength was 1.55Å
and a Pilatus detector at 936mm distance was used to give a scattering vector
(q¼ 4p/lsin(y), where 2y is the scattering angle) ranging from 0.14 to 4.1 nm 1.
X-TfiXAC2610(55–267) at 3.34, 1.67 and 0.84mgml 1 dissolved in 20mM Tris-HCl
pH 7.5 and 100mM NaCl was exposed in frames of 3 and 10 s, and only nor-
malized data without significant radiation damage in the small q range were
averaged to give the final scattering curve. Buffer scattering curves were collected
and subtracted from the sample’s scattering curve, taking into account its
attenuation. The scattering curves were normalized by the protein concentration to
check for interference effects61 or aggregation62 over the SAXS curves. Guinier
analysis was used to calculate the protein radius of gyration, Rg, and to evaluate the
monodispersity of the system. SAXS data analyses were performed using the
ATSAS package63. The determination of the pair-distance distribution function,
p(r), was conducted using the GNOM software64. After the p(r) calculation, 15 low
resolution ab initio envelopes for X-TfiXAC2610(55–267) were generated with
DAMMIN65 and aligned and averaged using the program suite DAMAVER66. The
normalized spatial discrepancy between the models was 0.562±0.011 and none
were rejected. Comparisons of the scattering experimental data and X-ray protein
models were performed using CRYSOL67.
X-TfeXAC2609 secretion analysis. GFP-labelled Xac strains (Xac WT pBRA GFP,
Xac DvirD4 pBRA GFP, Xac DvirD4 pBRA-virD4 GFP, Xac DvirB7 pBRA GFP,
Xac DvirB7 pBRA-virB7 GFP, Xac D2609 pBRA GFP, Xac D2609 pBRA-2609FL
GFP and Xac D2609 pBRA-2609Nt GFP; Supplementary Table 2) and E. coli
BL21(DE3)RIL ArcticExpress were grown separately in 2TY to log phase
(OD600 nm of 1.0), centrifuged, washed and resuspended to OD600 nm¼ 2.0. Xac
strains and E. coli were mixed at a 1:1 ratio. Xac alone or the mixtures (5 ml) were
spotted onto a nitrocellulose transfer membrane (GE Healthcare). The filter was
placed on LB agar media containing gentamicin and spectinomycin and main-
tained at 30 C for 12 h. Cells were washed away with running water for 2min, the
filter was blocked in 10% non-fat milk and then incubated with anti-X-TfeXAC2609
rabbit serum at 1:1,000 dilution. The primary antibody was detected using IRDye
800CW goat anti-rabbit IgG (LI-COR Biosciences) at 1:25,000 dilution. Mem-
branes were scanned using an Odyssey CLx infrared imaging system (LI-COR
Biosciences). Integrated fluorescence intensities with median background sub-
tracted were quantified using the Image Studio Lite (version 4.0) software package,
normalized to the values measured for the WT Xac:E. coli mixture, and the results
from seven independent experiments averaged. Western blots of total cellular
X-TfeXAC2609 produced by the Xac strains were carried out with the same anti-
bodies and documented using an Odyssey detection system as described above.
Xanthomonas growth in liquid and solid media. For analysis of Xac cell growth
in liquid medium, the Xac WT, DvirB7 and DvirD4 strains were inoculated in
triplicate in 2TY medium with a starting OD600 nm of 0.05, grown for 2 days at
30 C with agitation at 200 r.p.m. and the cell growth was monitored by measuring
OD600 nm and colony-forming unit (CFU) per ml at different time intervals.
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For analysis of cell growth on solid medium, 2.5 ml of Xac WT, DvirB7 and DvirD4
strains at OD600 nm of 0.05 were plated onto LB agar medium. Colonies were
resuspended in 1ml of 2TY after 32, 53 and 74 h of growth and serial dilutions
were plated on LB agar for CFU count.
Interbacterial growth competition experiments. Assays were performed in a
manner similar to that described previously7,33. In brief, CFP-labelled Xac strains
(Xac WT pUFR CFP, Xac DvirB7 pUFR CFP and Xac DvirB7 pUFR-virB7 CFP)
and E. coli DH5a YFP (Supplementary Table 2) were grown in 2TY to log phase
(OD600 nm¼ 1.0), centrifuged, washed and resuspended to OD600 nm¼ 0.5. These
Xac cells were then mixed with E. coli diluted at an 80:1 Xac:E. coli ratio. The
mixtures were spotted on LB agar plates containing gentamicin and allowed to
grow together as a co-culture at 30 C. Fluorescence micrographs were collected
after 48 h of incubation. Competition experiments of Xac cells (Xac WT GFP, Xac
DvirB7 GFP and Xac DvirD4 GFP; Supplementary Table 2) against C. violaceum
were performed as above without antibiotic selection and analysed after 24 h of
incubation. The results of competition experiments were quantified by determining
the CFU of Xac and E. coli per colony of a co-culture initiated with a 180:1 Xac:E.
coli mixture in which the initial Xac OD600 nm¼ 0.05. Xac strains used were Xac
WT pUFR, Xac DvirB7 pUFR and Xac DvirB7 pUFR-virB7 and the E. coli strain
was E. coli BL21(DE3)RIL ArcticExpress. Final Xac:E. coli ratios were calculated
after 38 h of competition by resuspending the colony, performing serial dilution
and plating the cells in LB agar media containing tetracycline for selection of E. coli
and ampicillin for selection of Xac.
Contact-dependent bacterial competition assays. GFP-labelled Xac strains (Xac
WT pBRA GFP, Xac DvirD4 pBRA GFP, Xac DvirD4 pBRA-virD4 GFP, Xac
DvirB7 pBRA GFP and Xac DvirB7 pBRA-virB7 GFP; Supplementary Table 2) and
E. coli BL21(DE3)RIL ArcticExpress were grown in 2TY to OD600 nm¼ 1.0,
collected by centrifugation, washed and resuspended to OD600 nm¼ 2.0. Xac strains
and E. coli were mixed at a 1:1 ratio. Xac alone or the mixtures were spotted onto a
0.22 mm polycarbonate membrane (Whatman) placed on LB agar plates containing
gentamicin and spectinomycin and the gfp fluorescence emission from the Xac
cells was documented after 24 h growth at 30 C. In parallel, no-contact experi-
ments were carried out by growing Xac cells on an intervening filter placed on top
of an E. coli BL21(DE3)RIL ArcticExpress lawn grown on LB agar plates containing
gentamicin and spectinomycin. The intervening filter prevents direct contact
between Xac and E. coli cells.
Microscopy analysis of Xac vs E. coli competition assays. Xac strains (Xac WT
pUFR CFP, Xac DvirB7 pUFR CFP and Xac DvirB7 pUFR-virB7 CFP or Xac WT
pBRA GFP, Xac DvirD4 pBRA GFP and Xac DvirD4 pBRA-virD4 GFP; see
Supplementary Table 2) and E. coli cells (DH5a YFP or BL21(DE3)RIL Arcti-
cExpress) were grown in 2TY with appropriate antibiotics to OD600 nm¼ 1.0,
centrifuged, washed, resuspended to OD600 nm¼ 2.0, mixed at a Xac:E. coli 1:1 ratio
and 2 ml spotted onto an LB agarose pad (1.5% agarose in 25% LB medium).
Interspecies competition was followed by fluorescence and brightfield microscopy.
Brightfield time-lapse data were acquired every 0.3 s. Image analysis and movie
edition were performed using ImageJ software, and Supplementary Movie 1 was
processed at 20 frames per second (that is, each second of the movie is equivalent
to 6 s of the experiment).
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